| Identification | Back Directory | [Name]
O-304 | [CAS]
1261289-04-6 | [Synonyms]
O-304
0 304
CS-2682
O-304;0 304
O-304 1261289-04-6
4-chloro-N-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide
Benzamide, 4-chloro-N-[2-[(4-chlorophenyl)methyl]-2,3-dihydro-3-oxo-1,2,4-thiadiazol-5-yl]- | [Molecular Formula]
C16H11Cl2N3O2S | [MOL File]
1261289-04-6.mol | [Molecular Weight]
380.25 |
| Chemical Properties | Back Directory | [density ]
1.50±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 10 mg/ml; DMSO: 10 mg/ml; DMSO:PBS (pH 7.2) (1:30): 0.03 mg/ml; Ethanol: slightly soluble | [form ]
A crystalline solid | [pka]
7.81±0.20(Predicted) | [color ]
White to off-white | [InChI]
InChI=1S/C16H11Cl2N3O2S/c17-12-5-1-10(2-6-12)9-21-16(23)20-15(24-21)19-14(22)11-3-7-13(18)8-4-11/h1-8H,9H2,(H,19,20,22,23) | [InChIKey]
WEDWLYRQKUTOAX-UHFFFAOYSA-N | [SMILES]
C(NC1SN(CC2=CC=C(Cl)C=C2)C(=O)N=1)(=O)C1=CC=C(Cl)C=C1 |
| Hazard Information | Back Directory | [Uses]
O-304 is a first-in-class, orally available pan-AMPK activator, which increases AMPK activity by suppressing the dephosphorylation of pAMPK. O-304 exhibits a great potential as a agent to treat type 2 diabetes (T2D) and associated cardiovascular complications [1][2]. | [in vivo]
O-304 increases glucose uptake in skeletal muscle, reduces β cell stress, and promotes β cell rest in diet-induced obese mice. O-304 reduces fasting plasma glucose levels and homeostasis model assessment of insulin resistance (HOMA-IR) in a proof-of-concept phase IIa clinical trial in type 2 diabetes (T2D) patients on Metformin[2]. | [References]
[1] Periodic Reporting for period 1-AMPK-DIAB (A small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novelinnovative drug for the treatment of type 2 diabetes). |
|
|